Alcon AG is projected to report Q3 2026 revenue of $2.73 billion and core EPS of $0.89, with its current $74.94 share price sitting below the average analyst target of $87.18.
Investors are intensely focused on the recovery of the Surgical segment, specifically whether constant-currency growth for premium intraocular lenses (Implantables) can break above the sluggish 1-2% seen in previous quarters.
This performance follows a strong Q2 where a 25% surge in equipment sales from the UNITY platform helped offset competitive pressures and a $402 million non-cash write-off.
Market watchers are also eyeing a projected $60 million U.S. government tariff refund expected this period, which could bolster margins as the company integrates its recent Neurotech acquisition.